Hepalink Pharma kicks off $585m Hong Kong listing
siro46 - stock.adobe.com
Shenzhen Hepalink Pharmaceutical Group launched its Hong Kong IPO this week, targeting proceeds of HK$4.53bn ($585m).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts